469 related articles for article (PubMed ID: 25882025)
21. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
22. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
23. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
24. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
25. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.
Lin JJ; Cardarella S; Lydon CA; Dahlberg SE; Jackman DM; Jänne PA; Johnson BE
J Thorac Oncol; 2016 Apr; 11(4):556-65. PubMed ID: 26724471
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib as first-line treatment for patients with epidermal growth factor receptor-mutated advanced lung adenocarcinoma: a single institution experience in Taiwan.
Lai SW; Ho CL; Dai MS; Chen WL; Chang PY; Wu YY; Perng CL; Lai CY
J BUON; 2014; 19(2):459-65. PubMed ID: 24965407
[TBL] [Abstract][Full Text] [Related]
27. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
28. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
30. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
31. Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Wu KL; Tsai MJ; Yang CJ; Chang WA; Hung JY; Yen CJ; Shen CH; Kuo TY; Lee JY; Chou SH; Liu TC; Chong IW; Huang MS
Lung Cancer; 2015 May; 88(2):187-94. PubMed ID: 25747806
[TBL] [Abstract][Full Text] [Related]
32. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG; Chang YL; Hsu YC; Wu JY; Yang CH; Yu CJ; Tsai MF; Shih JY; Yang PC
Oncologist; 2008 Dec; 13(12):1276-84. PubMed ID: 19060236
[TBL] [Abstract][Full Text] [Related]
33. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Izumi H; Touge H; Igishi T; Makino H; Nishii-Ito S; Takata M; Nakazaki H; Ueda Y; Matsumoto S; Kodani M; Kurai J; Takeda K; Sakamoto T; Yanai M; Tanaka N; Nirodi CS; Shimizu E
Int J Oncol; 2015 Mar; 46(3):989-98. PubMed ID: 25573239
[TBL] [Abstract][Full Text] [Related]
34. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
35. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
[TBL] [Abstract][Full Text] [Related]
36. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
37. Study of gefitinib maintenance in unselected patients with metastatic primary lung adenocarcinoma: A descriptive study.
Kumar R; Dubashi B; Kayal S; Lazzar SC; Barathi D; Kumar V
Indian J Cancer; 2017; 54(1):188-192. PubMed ID: 29199688
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
39. Disease flare after gefitinib discontinuation.
Akamatsu H; Ono A; Shukuya T; Tsuya A; Nakamura Y; Kenmotsu H; Naito T; Murakami H; Endo M; Nakajima T; Yamamoto N; Takahashi T
Respir Investig; 2015 Mar; 53(2):68-72. PubMed ID: 25745851
[TBL] [Abstract][Full Text] [Related]
40. [Epidermal growth factor receptor (EGFR) mutation status before and after acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma].
Ye SB; Li R; Shi SS
Zhonghua Bing Li Xue Za Zhi; 2017 Feb; 46(2):98-101. PubMed ID: 28173668
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
